Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 Apr;32(4):439-451.
doi: 10.1016/j.annonc.2021.01.003. Epub 2021 Jan 19.

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

E Baudin  1 , M Caplin  2 , R Garcia-Carbonero  3 , N Fazio  4 , P Ferolla  5 , P L Filosso  6 , A Frilling  7 , W W de Herder  8 , D Hörsch  9 , U Knigge  10 , C M Korse  11 , E Lim  12 , C Lombard-Bohas  13 , M Pavel  14 , J Y Scoazec  15 , A Sundin  16 , A Berruti  17 ; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Affiliations
Free article
Practice Guideline

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

E Baudin et al. Ann Oncol. 2021 Apr.
Free article

Erratum in

No abstract available

Keywords: characterisation; diagnosis; lung carcinoids; prognosis; therapy; thymic carcinoids.

PubMed Disclaimer

Conflict of interest statement

Disclosures EB has received honoraria from Novartis, Ipsen and Pfizer, research grants from Novartis and he is a member of Ipsen and Novartis speaker's bureau; MC has received research funding and speaker/advisory board honoraria from Ipsen, Novartis, Lexicon and AAA-Pharma; RGC has reported being an advisory board member for Novartis, Ipsen, AAA-Pharma and Pfizer and has received research grants from Pfizer; NF has received honoraria from Novartis, Ipsen, Pfizer, AAA-Pharma, Merck Sharp & Dohme and Merck Serono and research grants from Novartis and Merck Serono; PF has reported advisory board for Novartis, Ipsen, Merck Serono, Pfizer, Lexicon and Italfarmaco and has participated at steering committee for Novartis, Ipsen and Merck Serono; AF is a member of speaker's bureau and has received honoraria from Ipsen, Novartis and Sirtex and has received research grants from Novartis; WWdH has received research grants from Ipsen; DH has received honoraria from Novartis, Ipsen, Pfizer and ROTOP Pharmaka GmbH and research grants from Ipsen and he is a member of Ipsen and Novartis speaker's bureau; UK has received research funding and speaker advisory board honoraria from Ipsen and Novartis; CLB has reported being an advisory board member for Novartis, Pfizer, Ipsen and AAA-Pharma; MP has reported being an advisory board member for and received honoraria from Novartis, Ipsen, Pfizer and Lexicon and has received research grants from Ipsen and Novartis; AB is a member of Novartis speaker's bureau; all other authors have declared no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources